Details of the Drug Combinations

General Information of This Drug (ID: DML781M)

Drug Name

BAY1895344 DML781M

Synonyms

YBXRSCXGRPSTMW-CYBMUJFWSA-N; BAY-1895344; 1876467-74-1; BAY 1895344; (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine; UNII-7N13IK9LNH; 7N13IK9LNH; SCHEMBL17501318; MolPort-044-756-215; EX-A1662; AKOS032953592; ACN-051236; AC-30337; AK688481; (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BAY1895344 + Panobinostat	DCMC052	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.